| [1] |
LI Yanyang, WANG Yunjiao, LV Shichao.
Effects and mechanism of traditional Chinese medicine injection in prevention and treatment of cardiotoxicity induced by antineoplastic drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 572-577.
|
| [2] |
WANG Yali, HUO Xulei, CHEN Feng, LI Shenglan, ZHENG Xiaohong, WANG Can, LI Wenbin.
Research progress on the antitumor effect of nifurtimox
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 955-960.
|
| [3] |
CHEN Wenjie, WANG Yabing, CHEN Xiaolin, REN Junling, ZHAO Wanjun, CHEN bin.
Advances in the study of iodine-resistant differentiated thyroid cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 116-120.
|
| [4] |
.
Research progress in the cardiovascular adverse reactions of sorafenib and its mechanisms
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1300-1308.
|
| [5] |
YE Kaili, ZHENG Wen, YE Qifa, YANG Lan .
Mechanism of CDK1 participates in the development of hepatocellular carcinoma and its inhibitor application value
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1086-1094.
|
| [6] |
YANG Hechun, SHI Daohua .
Research progress of small molecule inhibitors that reverse tumor drug resistance by regulating tumor glucose metabolism
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 836-840.
|
| [7] |
HUANG Yiting, SHEN Aizong.
Clinical research progress of afatinib therapy for lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 474-480.
|
| [8] |
SUN Rensong, ZHANG Jianbin, FANG Jiani, LYU Xia, TANG Zeyao, TIAN Yan.
Application of chitosan nanoparticle served as drug delivery system for cancer therapy#br#
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 65-75.
|
| [9] |
SHI Lili, LIU Xingan, SHAN Guoyong.
Efficacy and safety of apatinib in the further line treatment for patients with advanced colorectal cancer failed after standard therapy and the preliminary analysis of efficacy predictors
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1388-1394.
|
| [10] |
WANG Gaoqing, JIANG Wei, HUA Yongfei.
Curative efficacy of retetrexel combined with laparoscopic hepatectomy in treatment of patients with primary liver cancer and its effects on liver function and CIART, AFP-L3 and GP73
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 752-756.
|
| [11] |
WANG Aijuan, GUO Yiyun, WANG Zhiqiu.
Apatinib combined with capecitabine in the treatment of advanced triple-negative breast cancer as third-line therapy: An observational study
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 433-439.
|
| [12] |
ZHAO Quanming, YANG Yang.
Progress in drug therapy for advanced triple-negative breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 475-480.
|
| [13] |
YANG Ke, LI Junling, DU Bin, TIAN Zhongqiu, JING Xiujuan.
Single-arm,one-center, exploratory clinical trial of albumin-bound paclitaxel second and more line therapy for advanced non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1281-1286.
|
| [14] |
HAO Ji-qing, SUN Gen-yun, SHEN Yu-xian.
Mechanisms of lumiracoxib on apoptosis in human lung cancer cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(1): 47-51.
|
| [15] |
SUN Sheng-kun<, LIU Bing<, LI Xiu-shen<, HOU Chun-mei<, HONG Bao-fa2, YU Xiao-dan<.
Targeting multiple signaling pathways in LNCaP prostate cancer cell line by trichostatin A
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(9): 1013-1016.
|
